about
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicityC5L2, a nonsignaling C5A binding proteinDisconnecting mitochondrial content from respiratory chain capacity in PGC-1-deficient skeletal muscleADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection.Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation.Transcriptional patterns in peritoneal tissue of encapsulating peritoneal sclerosis, a complication of chronic peritoneal dialysis.PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice.Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytesMitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathyCongenital chloride-losing diarrhea in a Mexican child with the novel homozygous SLC26A3 mutation G393W.Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia.Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells.Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants.Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth.Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity.Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.A paradoxical protective role for the proinflammatory peptide substance P receptor (NK1R) in acute hyperoxic lung injuryMacrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension.Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factorQuantification of PARP activity in human tissues: ex vivo assays in blood cells and immunohistochemistry in human biopsies.Placental soluble fms-like tyrosine kinase expression in small for gestational age infants and risk for adverse outcomes.Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1.Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst.Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation.PAD4 Deficiency Decreases Inflammation and Susceptibility to Pregnancy Loss in a Mouse Model.Endocytic internalization of adenovirus, nonspecific phagocytosis, and cytoskeletal organization are coordinately regulated in alveolar macrophages by GM-CSF and PU.1.The Use of Cytochrome C Oxidase Enzyme Activity and Immunohistochemistry in Defining Mitochondrial Injury in Kidney DiseaseLoss of kAE1 expression in collecting ducts of end-stage kidneys from a family with SLC4A1 G609R-associated distal renal tubular acidosisPlacental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia.Anti-T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus-mediated gene transfer.Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis.Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.Poly-ADP-ribose polymerase inhibition reduces mesenteric injury after cardiopulmonary bypass.Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5'-diphosphate-ribose) polymerase.
P50
Q24648835-F892AFE3-9527-4CAC-B091-60330801A112Q28565469-BBAF8B89-ED23-4513-BB64-EF0D260D519BQ30418706-DA0DAC0C-1CB7-49BE-8CD2-A7147D128507Q33423350-EB83D04E-DF44-472F-B7F3-7E0A60ABAA81Q34518432-D444D521-DD8D-4801-99BC-E596A4C7C5CEQ34521265-4CE4F61E-12D9-4AFD-9032-D6EC6F052C32Q34590067-99B33715-D281-44C3-A9DC-B806F305363AQ35370349-ACF661C1-8BAB-431A-97B5-861536206B69Q35586887-7247E972-C8CF-4873-93E1-BFB158E9290AQ35659099-C88353AF-F70C-442E-BFF6-3C89EDCA1CAFQ35768675-4872B98E-4E59-4BDB-A1AF-FA2928B0E019Q35871466-84B2614C-BCBE-4183-9394-2E8AEBB47EF9Q36001244-00DA83EA-8DED-40FC-8C1F-87C8FE08EF55Q36203242-B8E33750-368D-4C5B-895F-958E279A2EE1Q36266464-150F9AE0-8511-46EA-9194-AFBC69AD9D0DQ36285862-80E8B90E-3572-42FF-B5BB-4542A4D17109Q37042332-C50DD157-D0DC-4E2B-9696-A587F08D1ECBQ37373683-900A903A-CD2F-4999-93E3-EC598E07A934Q37406376-ABA10DED-6A95-489E-B7DF-A8ABBE1B6A84Q37555387-26A643BE-3BE9-4D98-8FB7-89B1BAE16B7AQ37670305-F93EAAA6-819C-4885-89EB-32BCC8BC10CEQ37922669-4E706203-A963-441C-8278-EF2046D78C10Q38374754-C2FBCE6E-C5E6-4945-8095-E69840EEBE5FQ38784644-2F39EB75-8A02-487C-A44F-5B97BFBCA677Q39427746-9067B802-5D9B-42FC-A46E-3AB8C4E2FF01Q39703468-48DACC25-3052-40B7-B3A3-710244CD51CCQ40389202-AC547F85-F00F-4ACA-85AE-C8393D0AC8E7Q40398309-2AD9E6C3-39E0-41D0-8B93-9573DEF1EAE1Q40688406-829BADB8-01ED-4CEF-A876-ADCE4F832ABCQ40983017-3D51809E-D772-45E1-A09C-050DA50DD0CAQ42204923-1738DABE-63FC-4315-98F3-0B551CEE47A9Q44121356-AB2AC13A-9E71-4E99-9C6E-FC6757F3BC98Q44342076-512861EA-91C6-4098-B080-DB355E789AABQ44749033-13C152E2-736E-44FD-B942-15244E796BD6Q44822122-F5F07A85-4521-4F3D-9E87-904814FA8BC2Q44843221-EFD872F4-0701-45A0-9CFA-9A3E9B3A4827Q44846989-9AD95123-5FB2-4C78-97FE-13BD0557BB53Q44940264-2A86196C-10BF-4EA3-B360-847065BCABC1Q45169267-C66DB5F0-E273-4F16-9B8D-8A1628C4E187Q45187456-640FFB4D-EA34-426A-B42D-0E5580F08BD4
P50
description
researcher ORCID ID = 0000-0002-4540-5728
@en
wetenschapper
@nl
name
Zsuzsanna K Zsengeller
@ast
Zsuzsanna K Zsengeller
@en
Zsuzsanna K Zsengeller
@es
Zsuzsanna K Zsengeller
@nl
type
label
Zsuzsanna K Zsengeller
@ast
Zsuzsanna K Zsengeller
@en
Zsuzsanna K Zsengeller
@es
Zsuzsanna K Zsengeller
@nl
altLabel
Dr. Zsuzsanna K. Zsengeller
@en
prefLabel
Zsuzsanna K Zsengeller
@ast
Zsuzsanna K Zsengeller
@en
Zsuzsanna K Zsengeller
@es
Zsuzsanna K Zsengeller
@nl
P106
P21
P2798
P31
P496
0000-0002-4540-5728